Hierarchically engineered multi-enzyme nanoreactors for in vitro drug biosynthesis and pathway transplantation into cells

This study demonstrates that hierarchically engineered MIL-101 metal-organic framework nanoreactors can encapsulate the entire six-enzyme violacein biosynthesis pathway to significantly enhance in vitro production, enable storage and reuse, and successfully deliver the functional multi-enzyme system into mammalian cells for intracellular drug biosynthesis.

The Gist

The Big Idea: Building a "Pocket-Sized Factory" Inside a Rock

Imagine you have a team of six specialized chefs (enzymes) who need to work together in a specific order to bake a very complex, purple cake (a drug called violacein).

In a normal kitchen (a test tube), these chefs are free-floating. They bump into each other, sometimes get distracted, and if the kitchen gets too hot, they might burn out or quit. Also, once they finish the cake, it's hard to clean up the kitchen to bake another one without throwing the chefs away.

The scientists in this paper asked: What if we could put all six chefs inside a tiny, durable, porous rock, so they stay together, stay safe, and can bake cakes over and over again?

They succeeded. They built a "nanoreactor" (a microscopic factory) using a special type of rock called a Metal-Organic Framework (MOF).

---

Step 1: The Problem with the Rock

The scientists started with a specific rock called MIL-101. Think of this rock like a sponge made of metal and organic strings.

• The Issue: The holes (pores) in the original sponge were too tiny (like a screen door). The chefs (enzymes) were too big to fit through the door.
• The Solution: They used a special "acid etching" technique to gently chew away parts of the rock, creating larger holes. They call this new, modified rock eMIL. Now, the holes are big enough for the chefs to walk right in.

Step 2: Moving the Chefs In

The scientists took their six purified enzymes (VioA through VioE, plus a helper enzyme called Catalase) and mixed them with the eMIL rock.

• The Result: The enzymes didn't just sit on the surface; they infiltrated the entire rock, filling up the holes like water soaking into a sponge.
• The Magic: Once inside, the rock acted like a protective bubble. Even if you heated the rock to temperatures that would normally kill the enzymes, they kept working. It's like putting fragile eggs in a reinforced steel box; the box takes the heat, and the eggs stay safe.

Step 3: Baking the Cake (Making the Drug)

When they added the ingredients (tryptophan) to the rock-filled factory:

1. It worked: The rock turned purple, proving the chefs were baking the cake (violacein).
2. It was better: Surprisingly, the rock factory produced three times more cake than the chefs working freely in a test tube.
   • Why? The rock seems to keep the chefs organized. Even though they started a bit slower (like a lag phase), they kept working steadily for a long time without getting tired or distracted.
3. It was reusable: You can wash the rock, add new ingredients, and bake again. They did this six times in a row! The free-floating chefs in a test tube can't do this; once they are done, they are usually lost in the liquid.
4. It was shelf-stable: They dried the rock out (lyophilization) and froze it. When they added water later, the chefs woke up and started baking again. This means these drugs could be shipped without needing a freezer truck (no "cold chain" needed).

Step 4: The "Trojan Horse" Mission (Inside the Cell)

This is the most exciting part. The scientists wanted to deliver this factory inside living human cells (specifically cancer cells).

• The Challenge: Getting big things into a cell is like trying to sneak a giant truck through a mouse hole. Usually, cells reject large proteins.
• The Trick: The eMIL rock is small enough and "friendly" enough that the cancer cells swallowed it whole (a process called endocytosis).
• The Surprise: Once inside the cell, the rock didn't break down immediately. It stayed intact in the cell's cytoplasm.
• The Payoff: The cell itself provided the ingredients (tryptophan and energy). The enzymes inside the rock used the cell's own resources to bake the purple cake (violacein) right inside the cancer cell.
• The Outcome: The cancer cell filled up with the toxic purple cake and died (apoptosis). Normal cells were less affected because they didn't have as much of the specific "fuel" (NADPH) that the cancer cells were hoarding.

Why This Matters (The "So What?")

1. Smart Drug Delivery: Instead of injecting a finished drug that might hurt healthy cells, we can inject a "smart factory" that only starts working when it finds a cancer cell with the right fuel.
2. Complex Chemistry: Most drugs are single molecules. This research shows we can deliver a whole team of enzymes (a pathway) to do complex chemistry inside the body, which was previously impossible.
3. No More Freezing: Because the rock protects the enzymes, these medicines could be stored in a backpack in a remote village without electricity and still work when you get there.

The Bottom Line

The scientists turned a porous rock into a biological Trojan Horse. They hid a team of six protein chefs inside a durable, heat-resistant, reusable, and dry-storage-friendly container. They successfully drove this container into cancer cells, where the chefs used the cell's own energy to build a toxic drug that killed the cancer from the inside out.

It's a massive step toward "programmable" medicine where we don't just deliver a pill, we deliver a miniature, self-sustaining factory to fix problems inside our bodies.

Technical Summary

1. Problem Statement

The authors address three critical limitations in current protein-based therapeutics and biotechnology:

• Delivery Barrier: Most protein drugs cannot cross the cell membrane to reach intracellular targets. Existing delivery methods (e.g., liposomes, microinjection) are often limited to ex vivo applications or lack efficiency for complex systems.
• Stability Issues: Proteins are inherently unstable, requiring cold chains and liquid formulations, which increases costs and limits accessibility.
• Conceptual Limitation: Current applications rely on single active proteins (e.g., antibodies). However, natural biological functions often require multi-enzyme pathways. There is no precedent for delivering a functionally synergistic, multi-protein biosynthetic pathway (more than 3 enzymes) into living cells.

2. Methodology

The study focuses on the violacein biosynthesis pathway, a natural product synthesis involving five enzymes (VioA–VioE) and a supporting catalase (6 enzymes total), converting L-tryptophan into the purple cytotoxic pigment violacein.

Material Engineering:

• Base Material: The researchers used MIL-101(Fe), a metal-organic framework (MOF) known for biodegradability and low toxicity.
• Hierarchical Etching: Unmodified MIL-101 has pores (~3.5 nm) too small for large enzymes (5–16 nm). The team applied a controlled etching process using acetic acid at 80°C to create etched MIL-101 (eMIL). This expanded the pore size distribution to a hierarchical range of 15–30 nm, allowing the infiltration of large, oligomeric enzymes without denaturation.
• Infiltration: Purified enzymes were infiltrated into eMIL particles by mixing them overnight at 4°C. Loading efficiency was determined to be nearly 100% (98–100%) for the 90-minute etched particles.

Experimental Workflow:

1. In Vitro Reconstitution: The pathway was reconstituted in solution and compared against the eMIL-encapsulated version.
2. Optimization: Parameters such as etching time, enzyme-to-MOF ratio, and the inclusion of catalase were optimized.
3. Stability Testing: The nanoreactors were subjected to heat stress (up to 50°C), lyophilization (freeze-drying), and storage to test stability.
4. Kinetic Analysis: Reaction kinetics, side-product formation, and turnover numbers were analyzed using UHPLC-MS/MS.
5. Cellular Delivery: eMIL nanoreactors loaded with the full pathway were incubated with mammalian cell lines (HeLa, 3T3, MCF-7) to assess intracellular uptake, pathway function, and cytotoxicity.

3. Key Contributions

• First Multi-Enzyme Pathway Transplantation: This is the first demonstration of delivering a complete, functional 6-enzyme biosynthetic pathway into living mammalian cells. Previous attempts were limited to 3 non-cooperating model proteins.
• Hierarchical MOF Design: The development of eMIL overcomes the size exclusion limit of traditional MOFs, enabling the co-encapsulation of diverse, large, and oligomeric enzymes while maintaining their activity.
• Pathway Transplantation Concept: The study introduces the concept of "pathway transplantation," where a synthetic metabolic pathway is delivered as a unit to hijack host cell metabolism (specifically NADPH and tryptophan) for in situ drug production.

4. Key Results

In Vitro Performance:

• Yield Enhancement: The eMIL nanoreactors produced 3-fold higher yields of violacein compared to free enzymes in solution (reaching ~145 µM vs. ~51 µM).
• Kinetic Reshaping: While free enzymes showed a rapid initial burst followed by a plateau, eMIL-encapsulated enzymes exhibited a prolonged lag phase but sustained steady-state production for longer, resulting in higher cumulative output.
• Stability & Reusability:
  • Thermostability: eMIL-encapsulated enzymes retained activity after 50°C heat treatment, whereas free enzymes were completely inactivated.
  • Storage: The nanoreactors survived lyophilization and -20°C storage with 50–75% activity retention, even without cryoprotectants.
  • Reusability: The nanoreactors were successfully reused for 6 consecutive cycles, producing nearly 5x more total product than a single cycle of free enzymes.
• Side Products: The MOF environment altered reaction dynamics, leading to increased accumulation of specific side products (DV, PV), suggesting the MOF modulates intermediate flow and enzyme kinetics.

Intracellular Delivery & Cytotoxicity:

• Uptake: eMIL particles were efficiently internalized by HeLa and 3T3 cells via endocytosis, localizing in the cytoplasm without nuclear entry.
• In Situ Synthesis: Once inside the cells, the pathway utilized endogenous substrates (tryptophan) and cofactors (NADPH) to synthesize violacein, confirmed by the appearance of purple fluorescence and UHPLC-MS/MS detection.
• Selective Cytotoxicity: The intracellular production of violacein induced apoptosis. The nanoreactors showed enhanced cytotoxicity toward cancer cells (HeLa, MCF-7) compared to normal cells (3T3, HEK-293). This selectivity is attributed to the Warburg effect in cancer cells, which provides higher levels of NADPH, fueling the pathway more efficiently.
• Control: Cells treated with an incomplete pathway (lacking VioB) showed no significant toxicity, confirming that the effect was due to violacein production, not the MOF carrier itself.

5. Significance

This work represents a paradigm shift in biocatalysis and drug delivery:

• Smart Therapeutics: It enables "environment-responsive" therapies where the drug is synthesized locally only in cells with specific metabolic profiles (e.g., high NADPH in tumors), minimizing systemic toxicity.
• Alternative to Gene Therapy: Instead of delivering genetic material to force a cell to produce a pathway (gene therapy), this approach delivers the functional machinery directly, avoiding risks associated with genomic integration and complex regulation.
• Logistical Advantages: The ability to lyophilize and store multi-enzyme systems at ambient temperatures addresses the cold-chain bottleneck of biologics.
• Future Applications: The platform is scalable and adaptable, offering a robust method for engineering complex metabolic pathways for green biotechnology, diagnostics, and next-generation precision medicine.